Piper Sandler initiates coverage on Twist Bioscience with Overweight rating
Piper Sandler analyst David Westenberg initiated coverage on Twist Bioscience with an Overweight rating and a price target of $85, indicating a positive outlook for the NASDAQ-listed biotechnology company.
*this image is generated using AI for illustrative purposes only.
Piper Sandler analyst David Westenberg has initiated coverage on Twist Bioscience with an Overweight rating and a price target of $85. The rating reflects a positive outlook on the company's performance and market position.
Analyst Rating and Price Target
The Overweight rating suggests that Twist Bioscience is expected to outperform the broader market or its sector peers. The assigned price target of $85 provides a specific valuation benchmark for investors.
Company Profile
Twist Bioscience is listed on the NASDAQ under the ticker symbol TWST. The company operates in the biotechnology sector, focusing on synthetic DNA and other genomic products.
What specific catalysts does Piper Sandler expect to drive Twist Bioscience's stock to the $85 price target?
How might Twist Bioscience's synthetic DNA technology impact the broader biotechnology sector in the coming years?
What are the potential risks or challenges that could hinder Twist Bioscience's ability to outperform its peers?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
